The company is poised to expand its commercial presence with significant upcoming launches in the pain and cystic fibrosis ... Alyftrek and the potential of VX-522 could further solidify Vertex ...

Learn more about whether Natera, Inc. or Vertex Pharmaceuticals Incorporated is a better investment based on AAII's A+ ...

VX-522: The multiple ascending dose (MAD ... Vertex increased its estimates for the number of people with cystic fibrosis in the U.S., Europe, Australia, and Canada from approximately 92,000 ...

VX-522: The multiple ascending dose (MAD ... Epidemiology and market opportunity update: Vertex increased its estimates for the number of people with cystic fibrosis in the U.S., Europe, Australia, ...

Vertex built its business treating the underlying genetic cause of cystic fibrosis (CF), a rare ... One is from a phase 1/2 study evaluating VX-522, a messenger RNA therapy that could treat ...

We now have five approved medicines in cystic fibrosis ... data releases that we expect to share this year. The first is VX-522, our mRNA program in partnership with Moderna for the last 10% ...

APOL1-Mediated Kidney Disease (AMKD) – Inaxaplin (VX-147) Vertex continues to enroll and dose patients ... life-shortening genetic diseases — cystic fibrosis, sickle cell disease and ...